Indivior Plc (LON:INDV) Stock Rating Reiterated by Analysts at Numis; Sanofi (SNY) Covered By 1 Bullish Analysts Last Week

Indivior PLC (LON:INDV) Logo

Among 12 analysts covering Sanofi-aventis Sa (NYSE:SNY), 1 have Buy rating, 2 Sell and 9 Hold. Therefore 8% are positive. Sanofi-aventis Sa had 25 analyst reports since October 15, 2015 according to SRatingsIntel. The company was upgraded on Wednesday, August 30 by HSBC. The company was downgraded on Thursday, December 10 by BNP Paribas. Cowen & Co maintained Sanofi (NYSE:SNY) on Monday, December 18 with “Hold” rating. The stock of Sanofi (NYSE:SNY) earned “Overweight” rating by Barclays Capital on Thursday, May 12. The firm earned “Hold” rating on Tuesday, September 5 by Cowen & Co. The stock of Sanofi (NYSE:SNY) earned “Sell” rating by JP Morgan on Friday, March 31. On Thursday, October 15 the stock rating was upgraded by Morgan Stanley to “Overweight”. The stock of Sanofi (NYSE:SNY) has “Equal-Weight” rating given on Wednesday, November 15 by Barclays Capital. The rating was initiated by Argus Research on Thursday, April 6 with “Buy”. The rating was downgraded by Berenberg on Thursday, May 11 to “Hold”. See Sanofi (NYSE:SNY) latest ratings:

08/02/2018 Broker: Bernstein Rating: Hold New Target: $45.0 Maintain
23/01/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Downgrade
18/12/2017 Broker: Cowen & Co Rating: Hold New Target: $48.0 Maintain
06/12/2017 Broker: Bank of America Rating: Hold Downgrade
01/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Underweight Downgrade
15/11/2017 Broker: Barclays Capital Old Rating: Underweight New Rating: Equal-Weight Upgrade

Today, Numis restate their “Buy” rating on Indivior Plc (LON:INDV)‘s stock in analysts note revealed.

Indivior PLC, together with its subsidiaries, develops, makes, and sells buprenorphine prescription drugs for the treatment of opioid dependence worldwide. The company has market cap of 3.34 billion GBP. The company's product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia. It has a 57.33 P/E ratio. It markets and promotes SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex.

Among 8 analysts covering Indivior Plc (LON:INDV), 6 have Buy rating, 0 Sell and 2 Hold. Therefore 75% are positive. Indivior Plc has GBX 640 highest and GBX 140 lowest target. GBX 486.25’s average target is 6.03% above currents GBX 458.6 stock price. Indivior Plc had 117 analyst reports since July 29, 2015 according to SRatingsIntel. Cantor Fitzgerald maintained Indivior PLC (LON:INDV) rating on Monday, June 6. Cantor Fitzgerald has “Hold” rating and GBX 215 target. Numis Securities maintained the stock with “Buy” rating in Tuesday, July 11 report. Stifel Nicolaus maintained Indivior PLC (LON:INDV) on Friday, June 24 with “Buy” rating. The firm has “Buy” rating by Numis Securities given on Friday, July 29. The company was maintained on Monday, April 9 by Jefferies. The stock of Indivior PLC (LON:INDV) has “Neutral” rating given on Thursday, October 26 by Citigroup. The stock has “Buy” rating by Deutsche Bank on Friday, July 8. Stifel Nicolaus maintained the shares of INDV in report on Wednesday, August 17 with “Buy” rating. The stock of Indivior PLC (LON:INDV) earned “Buy” rating by Numis Securities on Thursday, July 27. On Thursday, February 23 the stock rating was maintained by Deutsche Bank with “Buy”.

The stock decreased 0.52% or GBX 2.4 during the last trading session, reaching GBX 458.6. About 2.90 million shares traded or 11.73% up from the average. Indivior PLC (LON:INDV) has 0.00% since May 2, 2017 and is . It has underperformed by 11.55% the S&P500.

Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company has market cap of $97.39 billion. The firm operates in two divisions, Pharmaceuticals and Vaccines. It currently has negative earnings. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis.

The stock decreased 0.48% or $0.19 during the last trading session, reaching $39.13. About 974,888 shares traded. Sanofi (NYSE:SNY) has declined 13.31% since May 2, 2017 and is downtrending. It has underperformed by 24.86% the S&P500.

Sanofi (NYSE:SNY) Ratings Chart